

# Evaluation of the Patient with Common and Not So Common Pulmonary Disorders

Wendy L. Wright,  
DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP  
Adult/Family Nurse Practitioner  
Owner – Wright & Associates Family Healthcare @  
Amherst and @ Concord, New Hampshire

Wright, 2022

1

1

## Objectives

- Upon completion of this lecture, the participant will be able to:
  - Identify various causes of chronic cough and other pulmonary issues
  - Discuss the workup for patients with a chronic cough and other pulmonary disorders
  - Discuss treatment options for the patient with a chronic cough and other pulmonary disorders

Wright, 2022

2

2

## Definition

- **Chronic Cough**

- Typically defined as a cough that lasts 8 weeks or longer
- Can cause significant distress for the individual affected by the cough
- It is estimated to occur in 40% of the population, at some point in one's lifetime
- One of the most common presenting symptoms in adults seeking primary care

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

3

3

## Traditional Approach...

- **Chronic cough was divided into two possible causes:**
  - Upper respiratory tract conditions
  - Lower respiratory tract conditions

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

4

4

## Current Approach

- “One airway, one disease”
- Even individuals with upper airway conditions such as post-nasal drip have elevated levels of inflammatory mediators in the lower airway

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

5

5

## Look for Obvious Causes Based On History and PE

- Infection (Acute bacterial rhinosinusitis)
- Smoking or recent smoking cessation (cough will often resolve 4 weeks after cessation)
- ACE inhibitor
  - Can occur at any time on an ACE inhibitor
- Cerumen

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

6

6

## Look for Obvious Causes Based On History and PE

- Congestive heart failure
  - S3, edema, DOE, PND, weight gain
- Standard workup
  - Chest X-ray (every patient needs)
  - Consider spirometry
  - Mantoux (if risk factors)

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

7

7

### Most Common Causes

- Medication induced
- Asthma
- GERD
- Postnasal drip syndrome

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

8

8

## Less Common Causes

- Account for 5-10% of cough (in total)
  - Bronchiectasis
  - Bronchogenic carcinoma
  - Chronic aspiration
  - COPD
  - CHF
- Interstitial lung disease
- Neuromuscular disorders
- Pertussis
- Psychogenic cough
- Sarcoidosis
- Tuberculosis

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

9

9

## Most Common Etiology

- Most common:
  - Post-nasal drip syndrome
  - Post-infectious cough
  - GERD
  - Cough variant asthma
  - Medication induced
- Estimated that in non-smokers, immunocompetent individuals with a normal chest X-ray
  - Post-nasal drip, asthma, and GERD account for 92 – 100% of chronic cough cases (post-nasal drip most common)

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

10

10

# Post-nasal drip syndrome

Wright, 2022

11

11

## Post-nasal drip syndrome

- Most common cause of chronic cough
- Mechanism to clear mucous which has drained into the posterior pharynx and airway
- Twenty percent (20%) of individuals with post-nasal drip are unaware of the presence of mucous in posterior pharynx
- Physical examination is non-specific but may suggest:
  - Cobblestoning
  - Presence of mucous in posterior pharynx

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

12

12

## New Terminology: Upper Airway Cough Syndrome (UACS)

- **Post-nasal drip syndrome**
  - Acute rhinosinusitis (ARS and ABRS)
  - Nonallergic rhinitis
    - Perennial rhinitis
    - Rhinitis of pregnancy
    - Gustatory rhinitis
    - Rhinitis medicamentosa
    - Nonallergic rhinitis with eosinophilia
  - Allergic rhinitis

<http://emedicine.medscape.com/article/1048560-overview> accessed 06-04-2017

Wright, 2022

13

13

4

## Impact of Allergic Rhinitis in the United States

- 17 million individuals in US have diagnosed allergic rhinitis
  - This accounts for 14% of the US population
  - Recent prevalence studies show that it may be present in 31.5% of all adults
- 10-20% of this number is children
  - Most common chronic medical condition of childhood
- 79.5 million Americans have undiagnosed allergic rhinitis
- Average age of onset: 10 years of age

Wright, 2022

14

5

## Pathophysiology of Allergic Rhinitis

- Results from repeated exposure to allergens in the individual already equipped with the genetic predisposition
- Upon exposure to an allergen, there is a release of IgE antibodies
- IgE antibody binds with the antigen
- It then attaches itself to the mast cells on the nasal and bronchial mucosa
- Release of numerous chemical mediators; including leukotrienes and histamine

Wright, 2022

15

6

## Asthma and Allergic Rhinitis: Closely Related Diseases

- Similar risk factors, pathophysiology, patterns of inflammation and triggers
- Approximately 74%-80% of children and adults with asthma have associated rhinitis
- Approximately 5-15% of individuals with allergic rhinitis will develop asthma
- It is said that if you don't treat the nose in the patient with asthma, you will never get their asthma under control

Wright, 2022

16



7

# One Airway, One Disease

Wright, 2022

17

8


## Symptoms of Allergic Rhinitis

- Nasal congestion
- Sneezing
- Profuse watery discharge from nose and/or eyes
- Itching of nose, eyes, and palate
- Frequent clearing of the throat
- Nose picking
- Grimacing or twitching
- **Cough**
- Mouth breathing
- Fatigue
- Irritability
- Decreased appetite
- Decreased hearing
- Hoarse voice
- Decreased smell
- Sniffling
- Epistaxis

Wright, 2022

18

9



19


0



Wright, 2022

20

1



21

2




22

3



23

4



24

5

# Treatment Options

Wright, 2022

25

6

## Environmental Modification

- Environmental modification is recommended as first line therapy for the individual with allergic rhinitis

Wright, 2022

26

7

## Reliever Medications

- Antihistamines
  - First Generation
  - Second Generation
- Decongestants

Wright, 2022

27

8

## First Generation Antihistamines

- Number of Products Available
  - **Brompheniramine (Bromfed, Dimetapp)**
  - **Chlorpheniramine (Chlor-trimeton, Allerest)**
  - **Clemastine (Tavist)**
  - **Diphenhydramine (Benadryl)**
  - **Hydroxyzine (Atarax)**
  - **Promethazine (Phenergan )**
  - **Triprolidine hydrochloride (Actifed)**

Wright, 2022

28

9

## Second Generation Antihistamines

- These have emerged as first line rescue medications
  - Loratadine (Claritin)
    - 2 years and up: 5 - 10mg daily
  - Desloratadine (Clarinex)
    - 6 months of age and up
    - 1 mg – 5 mg daily depending upon age

Wright, 2022

29

0

## Second Generation Antihistamines

- Fexofenadine (Allegra)
  - 60mg bid; 180 mg once daily: 12 years and up
  - 30 mg bid: age 2 years of age – 11 years of age
  - 15 mg bid: 6 months – 1 year (urticaria)
- Cetirizine (Zyrtec)
  - 2-5 years: 2.5-5 mg daily
  - 6 or greater: 5-10 mg daily<sup>6</sup>
- Levocetirizine (Xyzal)
  - 1.25 mg once daily: 2 – 5 years of age
  - 2.5 mg once daily: 6 – 11 years of age
  - 2.5 mg – 5 mg once daily: 12 years of age and older

Wright, 2022

30

## Decongestants may offer some benefit

- According to a survey of allergy patients who take medications more than 180 days per year
  - 9 out of 10 seasonal allergy patients experience nasal congestion
  - Nasal congestion is the single most frustrating symptom for seasonal allergy patients
  - Over 90% of seasonal allergy patients with nasal congestion want faster relief

Source: IAS 2004

Wright, 2022

31

31

## Controller Medications

- Mast Cell Stabilizers
- Nasal Corticosteroids
  - Preferred controller therapy
- Nasal Antihistamines
  - (seasonal, perennial, and allergic rhinitis)
- Nasal Anticholinergics
- Leukotriene Antagonists
  - Recommends against using monotherapy
- Acupuncture (evidence exists to support)

Wright, 2022

32

32



3

## Inhaled Nasal Corticosteroids

- Numerous Products
  - Beclomethasone dipropionate (Qnasal, Beconase A!) \* 4 years of age and older
  - Budesonide (Rhinocort Aqua) \*\*6 and older
  - Flunisolide (Nasarel) \*\*6 and older
  - Fluticasone (Flonase, Veramyst) \*\*4 and older
  - Mometasone (Nasonex) \*\*Age 2 and older
  - Triamcinolone acetonide (Nasacort AQ) \*\*2 and older
  - Ciclesonide (Omnaris, Zetonna) \*\*6 years of age and older

Wright, 2022

33

4

## According to the Guidelines

- Corticosteroids are first line for the person with moderate to severe allergic rhinitis
- Very potent and effective
  - Most corticosteroids are equally efficacious
- Many are now available OTC

Wright, 2022

34

5

## Inhaled Corticosteroids

- Most potent anti-inflammatory on the market
- Side effects
  - Nasal irritation, epistaxis
- Precautions
  - High dosages: Increased systemic absorption leading to HPA axis suppression

Wright, 2022

35

6

## Leukotriene Receptor Antagonists

- Cysteinyl leukotriene production in the body has been associated with airway edema, smooth muscle constriction and the inflammatory process
- These medications block the leukotriene receptors which in turn is able to prevent inflammation and bronchoconstriction

Wright, 2022

36

7

## Montelukast (Singulair)

- (Montelukast) Singulair
  - 4 mg tablet for children 12 months – 5 years of age
  - 5mg at bedtime for ages 6-14
  - 10mg at bedtime for ages 15 and older
  - Caution: mood destabilization; now officially a boxed warning

Wright, 2022

37

## Sublingual Allergen Extract

- Oralair (other products: ragwitek, grastek)
  - Treatment of allergic rhinitis with or without allergic conjunctivitis
  - For those allergic to certain grass pollens age 10 – 65 years
  - First dose administered in healthcare providers office with observation for minimum of 30 minutes
    - If tolerated, patient may then use at home
    - Once daily, initiated 4 months before allergy season
  - Box warning: anaphylaxis

Wright, 2022

38

38

9

## Immunotherapy

- Reserved for the most severe cases; those unresponsive to treatment, unwilling or unable to tolerate pharmacologic treatments
- Successful therapy causes an initial rise in IgE levels and then a subsequent decline in levels and symptomatology
- Treatment for 6 months or longer is required before benefits will be seen
- Entire course of treatment: 3-5 years

Wright, 2022

39

## Other Options

- Azelastine (Astelin, Astepro)
- Azelastine/fluticasone (Dymista)
- Ipratropium bromide (Atrovent)
  - Perennial and gustatory rhinitis
- Rhinitis medicamentosa
  - D/c medication
  - Can be accomplished with prednisone and introduction of nasal corticosteroid

Wright, 2022

40

40

## Post-infectious and Infectious Cough

Wright, 2022

41

41

### Reported Cases of Pertussis Are Highest in Adolescents and Adults ...

- ~10,000-25,000 cases of pertussis are reported in the US every year<sup>1</sup>
- ~60% of reported cases occur among adolescents and adults<sup>2</sup>
- Reported cases are the tip of the iceberg
  - Estimated actual cases among adolescents and adults: 800,000-3.3 million per year<sup>3</sup>



Courtesy of the Centers for Disease Control and Prevention (CDC).


*"Despite increasing awareness and recognition of pertussis as a disease that affects adolescents and adults, pertussis is overlooked in the differential diagnosis of cough illness in this population."<sup>4</sup>*

References: 1. CDC. (Published July 9, 2009 for 2007). *MMWR*. 2007;56(53):1-94. 2. CDC. Data on file (Pertussis Surveillance Reports), 2003-2008. MKT 17595 (2003-2006); MKT 18596 (2007); MKT 18761 (2008). 3. Cherry JD. *Pediatrics*. 2005;115(5):1422-1427. 4. CDC. *MMWR*. 2005;55(RR-14):1-16.

42

42

## Number of Medical Visits Needed in Adults with Pertussis



N=2472 Massachusetts adults.

Wright, 2022


43

Centers for Disease Control and Prevention. *MMWR*. 2006;55(RR-17):1-43.

43

## Diagnostic Tests for Pertussis

- NP culture on special media  
(Regan-Lowe, Bordet-Gengou)
- PCR
- Serologic tests
- Increased WBC with an absolute lymphocytosis
- DFA—variable sensitivity/specificity



Copyright © 2016 NuCera Medical Art. All rights reserved. www.nucera.com.

44

44

5

## Treatment of Cases and Chemoprophylaxis of Close Contacts

- Erythromycin estolate or erythromycin ethylsuccinate (EES) 40-50 mg/kg/day (max 2 g/day) in 2-4 divided doses for 7-14 days<sup>1\*</sup>
- Azithromycin 10-12 mg/kg/day (max 500mg/day) 1 dose/day for 5 days<sup>†</sup>
- Clarithromycin 15-20 mg/kg/day (max 1g/day) in 2 divided doses for 7 days

Reference:

1. Halperin SA. Pertussis Control in Canada [letter]. *CMAJ*. 2003;168(11):1389-1390.

\* Use caution when using macrolides, especially erythromycin, in infants less than 2 weeks old.

† Azithromycin may be given as 10-12 mg/kg/day (max 500 mg/day) on day 1 and 5 mg/kg/day (max 250 mg/day) on days 2-5.

Wright, 2022

45

6

## Treatment of Cases and Chemoprophylaxis of Close Contacts (cont'd)

- For patients allergic to macrolides:
  - Trimethoprim-sulfamethoxazole 8mg TMP/40mg SMX/kg/day (max 320mg TMP/1600mg/day) in 2 divided doses for 14 days<sup>1</sup>
- All of these agents reduce transmission of *B pertussis* and ameliorate early symptoms<sup>2</sup>
- No antibiotic lessens the severity or shortens the duration of cough in patients who are already experiencing paroxysmal episodes<sup>1</sup>
- Penicillins/cephalosporins are not effective

References:

1. Edwards KM, et al. In: Plotkin SA, et al, eds. *Vaccines*. 1999:293-344.

2. CDC. The Pink Book, 7th ed. 2002:75-88. Available at: [www.cdc.gov/nip/publications/pink/pert.pdf](http://www.cdc.gov/nip/publications/pink/pert.pdf). Accessed March 15, 2022.

Wright, 2022

46

# Bronchitis

Wright, 2022

47

47

## Bronchitis

- 90% - 95% of cases are viral
- American College of Chest Physicians
  - Ipratropium bromide
  - Albuterol
  - Prednisone
  - Cough suppressants
- If bacterial, mycoplasma must be considered
- Consider *B. pertussis*

Wright, 2022

<http://www.aafp.org/afp/2010/1201/p1345.html> accessed 08-01-2015

48



## January 2016: CDC/ACP Guideline

- Management of Acute Respiratory Tract Infections (ARTIs)
  - Number one reason for antimicrobial use in adults
  - Antibiotics prescribed for more than 100 million adult visits per year with 41% for ARTIs
  - Thought to be large contributor to antimicrobial resistance
  - 1 in every 5 ER visits for drug reactions is result of antibiotic use

<http://annals.org/article.aspx?articleid=2481815> accessed 05-10-2016

Wright, 2022

49

49

## Bronchitis

- Bronchitis is characterized by inflammation of the bronchial tubes (bronchi), the air passages that extend from the trachea into the small airways and alveoli
- Lasts for up to 6 weeks
- Accompanied by constitutional symptoms

<http://annals.org/article.aspx?articleid=2481815> accessed 05-10-2016

Wright, 2022

50

50

## CDC/ACP

- Bronchitis
  - Use of antibiotics in this patient population is not warranted
  - If pneumonia is suspected, work-up and treat accordingly
  - Treatment now aimed at symptomatic management

<http://annals.org/article.aspx?articleid=2481815> accessed 05-10-2016

Wright, 2022

51

51

## Etiology

- Etiology:
  - Majority of cases are viral
    - Influenza, adenovirus, rhinovirus, coronavirus, parainfluenza virus and RSV
  - If infection is bacterial:
    - *Mycoplasma pneumoniae*
    - *Chlamydia pneumoniae*

<http://annals.org/article.aspx?articleid=2481815> accessed 05-10-2016

Wright, 2022

52

52

## Symptoms

- Cough
- Dyspnea
- Sputum production
- Fever/chills
- Malaise
- Chest pain
- Often accompanied by other URI symptoms

<http://annals.org/article.aspx?articleid=2481815> accessed 05-10-2016

Wright, 2022

53

53

## Recommendations for Treatment

- Cough expectorants
  - guaifenesin
- Cough suppressants
  - dextromethorphan, codeine
- First generation antihistamines
  - diphenhydramine
- Decongestants
  - phenylephrine
- Beta agonists
  - albuterol

<http://annals.org/article.aspx?articleid=2481815> accessed 05-10-2016

Wright, 2022

54

54

## Other Options: Post-infectious cough

- Ipratropium bromide
- ICS
- Corticosteroids
  - 30 – 40 mg / day x 3 – 5 days
  - Single daily dose
  - No taper necessary

<http://journal.publications.chestnet.org/pdfaccess.ashx?ResourceID=2118520>  
accessed 05-10-2016

Wright, 2022

55

55

## Gastroesophageal Reflux Disease (GERD)

Wright, 2022

56

56

## EE

- 52-year-old female presents with a 6 month – 1 year history of cough; denies chest pain, SOB, abdominal pain. Believes that it is aggravated by eating. No association with exercise. Has not been ill.
- Aggravating factors:
  - Foods
- Alleviating factors:
  - None
- Medications:
  - Escitalopram 5 mg one daily

Wright, 2022  
57

57

## EE (Continued)

- PMH
  - Anxiety disorder
  - Postmenopausal
  - Overweight
  - L5-S1 disc surgery
- No previous work-up for symptoms
- Physical Examination
  - HEENT: unremarkable
  - Lungs clear
  - Heart: S1, S2; RRR; no murmurs
  - Abdomen: unremarkable

Wright, 2022  
58

58

## What is GERD?

- Heartburn is one symptom of GERD
- This is characterized by:
  - Reflux of food and acid from stomach into esophagus
  - Often associated with esophageal inflammation
  - May be associated with mucosal injury or even cancer
    - Erosive esophagitis and/or Barrett's

Wright, 2022  
59

59

## EE (Continued)

- Most likely diagnosis is:
  - Cough x 1 year
  - Spirometry: normal
  - ECG: normal
  - Chest Xray: normal
  - Mantoux: normal

Wright, 2022

60

60

## GERD

- Heartburn and regurgitation are the most common symptoms of GERD
- GERD is a complex of different abnormalities
  - To simplify, reflux of gastric contents into the esophagus resulting in symptoms and / or complications

Wright, 2022

61

61

## Etiology of Heartburn and GERD

- Relaxation of the lower esophageal sphincter (LES) temporarily relaxes
  - Allows reflux of stomach acid into the esophagus
  - Normally, gravity and peristalsis clear material from the esophagus and the saliva that we swallow neutralizes the remaining esophageal acid
  - Heartburn occurs when any one of these mechanisms are impaired

Wright, 2022

62

62

## Cause of Lower Esophageal Sphincter Relaxation

- Relaxation or weakening of the LES can be caused by:
  - Eating certain foods
    - Onions, garlic, black pepper
  - Pressure on the stomach because of an individual's weight
  - Frequent bending and lifting, particularly after eating
  - Vigorous exercise

Wright, 2022

63

63

## Cause of Lower Esophageal Sphincter Relaxation

- Relaxation or weakening of the LES can be caused by:
  - Pregnancy
    - Progesterone relaxes LES; slows peristalsis and increases retention of partially digested food and acid
  - Medications also can decrease LES pressure
    - CCB's, hormone replacement therapy, muscle relaxants, beta blockers
    - Alpha-blockers
    - Nitrates
  - Pathophysiologic mechanisms
    - Hiatal hernia and gastric acid hypersecretion
    - Zenker's diverticulum

Wright, 2022

64

64



## Etiology

- Several other defects thought to contribute to heartburn and GERD
  - Abnormal esophageal epithelial resistance
  - Abnormalities of gastric emptying
  - Gastric distention
  - Abnormal acid production

Wright, 2022  
65

65

## Diagnosis of Heartburn and GERD

- Diagnosis of heartburn is usually made with history and physical examination
  - Usually, this is all that is needed
- Many clinicians will try routine treatments first and assess for response prior to ordering a variety of tests
- EGD – is not needed to make diagnosis

Wright, 2022

66

66

# Treatment Options

Wright, 2022

67

67

## ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease

Philip O. Katz, MD, MACG<sup>1</sup>, Kerry B. Dunbar, MD, PhD,  
Felice H. Schnoll-Sussman, MD, FACP, Katarina B. Greer,  
MD, MS, FACP, Rena Yadlapati, MD, MSHS and Stuart Jon  
Spechler, MD, FACP

Am J Gastroenterol 2022;117:27–56.  
<https://doi.org/10.14309/ajg.0000000000001538>; published  
online November 22, 2021

Wright, 2022

68

68

## Nonpharmacologic Treatment Options

- Dietary Modification
  - Avoidance of meals within 2-3 hours of bedtime
  - Avoidance of tobacco/cigarette related products
  - Avoidance of trigger foods
  - Elevate the head of the bed by 2-3 inches
  - Weight loss in overweight or obese individuals

Wright, 2022  
69

69

## ACG Guidelines

- PPI therapy is now first line
  - For those without alarm findings, PPI x 8 weeks is the recommended treatment
  - Discontinue after 8 weeks if patient has responded to the PPI
- No diagnostic testing needed
- No need for repeat endoscopy, unless patient does not respond adequately to PPI x 8 weeks

Wright, 2022

70

70

## Alarm Findings

- Weight loss
- Dysphagia
- Iron deficiency anemia
- Black/bloody stools
- Chest pain
- Failure to respond to PPI therapy

Wright, 2022

71

71

## Proton Pump Inhibitors

Wright, 2022

72

72

## Mechanism of Action

- PPIs
  - Suppress gastric acid production by blocking parietal cell hydrogen/potassium ion adenosine triphosphatase
  - Known as the proton pump
  - This is the final pathway involved in acid secretion
  - Remember...PPI's affect only those pumps which are active
    - Not all pumps are active at the same time
  - 25% of new proton pumps are synthesized daily

Wright, 2022  
73

73

## Proton Pump Inhibitors

- Omeprazole (Prilosec)
- Lansoprazole (Prevacid)
- Esomeprazole (Nexium)
- Rabeprazole (AcipHex)
- Pantoprazole (Protonix)
- Dexlansoprazole (Dexilant)

Wright, 2022

74

74

## PPIs

- Best efficacy when taken in the morning
  - PPIs only bind to proton pumps that are actively secreting acid
  - Ideally, 30–60 minutes before breakfast for once-daily dosing and 30–60 minutes before breakfast and dinner for twice-daily dosing
- If an endoscopy is needed, stopping PPIs 2-4 weeks before endoscopy is beneficial for optimal findings/results

Wright, 2022

75

75

## Switching PPIs

- There is a wide variation in individual intragastric pH
- Sometimes, very helpful to try changing a PPI for an individual having suboptimal response
  - In one study, patients taking lansoprazole and having suboptimal response were changed to bid lansoprazole vs. once daily esomeprazole with equal efficacy

Wright, 2022

76

76

## Refractory GERD

- Considered refractory when individual is on two times daily PPI for 8 weeks and is continuing to have symptoms

Wright, 2022

77

77

## Proton Pump Inhibitors

- Recent studies have shown an increased risk of:
  - Osteoporosis
    - Should take calcium citrate NOT carbonate
    - Carbonate – i.e. Tums needs an acidic environment
  - Pneumonia
    - Diminished acid protection
  - B12 deficiency
  - C. difficile related infections
  - ? Link with dementia
  - Chronic kidney disease
  - Hypomagnesemia

Wright, 2022

78

## What Does ACG Say?

- “PPIs are the most effective medical treatment for GERD. Some medical studies have identified an association between the long-term use of PPIs and the development of numerous adverse conditions including intestinal infections, pneumonia, stomach cancer, osteoporosis-related bone fractures, chronic kidney disease, deficiencies of certain vitamins and minerals, heart attacks, strokes, dementia, and early death. “
- “Those studies have flaws, are not considered definitive, and do not establish a cause-and-effect relationship between PPIs and the adverse conditions.”
- “High-quality studies have found that PPIs do not significantly increase the risk of any of these conditions except intestinal infections.”

Wright, 2022

79

79

## Combination Therapy

- Omeprazole/sodium bicarbonate (Zegerid)
  - Indications
    - Gastric and duodenal ulcer
    - Erosive esophagitis
    - Symptomatic GERD

Wright, 2022

80

80



## Interaction with Clopidogrel

- Interaction has been documented in a few studies but larger studies do not confirm true interaction
- Does not necessarily seem to be a class effect
- Most interaction to least interaction
  - Omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prevacid)
  - Lowest interaction: pantoprazole (Protonix) and dexlansoprazole (Dexilant)

Wright, 2022

81

81

## Stopping PPIs

- Try tapering rather than abruptly stopping
- Try replacing PPI dose with H2RA; as needed antacids
- Lowest dose of PPIs possible to control symptoms, if unable to discontinue

Wright, 2022

82

82

EE

- Patient returns 1 month after initiating treatment with a PPI; significant improvement in cough; very rare in occurrence

Wright, 2022  
83

83

Asthma

Wright, 2022

84

84

## Asthma is...

- Derived from the Greek word for panting or breathlessness
- Recurrent airflow obstruction caused by chronic airway inflammation with a superimposed bronchospasm
- Leads to... wheezing, breathlessness and a cough

*Guidelines for the Diagnosis and Management of Asthma—Update on Selected Topics 2002.* NIH, NHLBI. June 2002.  
NIH publication no. 02-5075.

Wright, 2022

85

85

## Pathophysiology of Asthma

- Genetic predisposition
  - Chromosome: 5Q31-Q33
- Results from repeated exposure to allergens in the individual already equipped with the genetic predisposition
- Upon exposure to an allergen, there is a release of IgE antibodies
- IgE antibody binds with the antigen

Wright, 2022

86

86

## Pathophysiology of Asthma


- IgE/allergen complex - then attaches itself to the mast cells on the nasal and bronchial mucosa
- Release of numerous chemical mediators

Wright, 2022

87

87

## Consequences of Inflammation in Asthma



Wright, 2022

88

88

## Asthma is...

- A disease of:
  - Inflammation
    - Primary Process
  - Hyperresponsiveness
  - Airway bronchoconstriction
  - Excessive mucous production

Wright, 2022

89

89

## Diagnosis of Asthma

Wright, 2022

90

90

## Diagnosis of Asthma

- History and Physical Examination
- Spirometry is needed to make diagnosis
- Monitoring:
  - Peak Flow Meters

Wright, 2022

91

91

## Symptoms and Signs of Asthma in Children and Adults


- Coughing, particularly at night or after exercise
- Wheezing
- Chest tightness
- SOB
- COUGH that lingers x months

Wright, 2022

92

92

## Methods for Measuring Airway Caliber



Wright, 2022

93

93

## Classification of Asthma Severity (Youths ≥ 12 Years of Age and Adults)

### Initial Diagnosis: Determine Severity and Treatment Needed

Components of Severity		Intermittent	Mild	Persistent Moderate	Severe
	<b>Symptoms</b>	≤ 2 days/week	> 2 days/week but not daily	Daily	Throughout the day
	Nighttime awakenings	≤ 2x/month	3-4x/month	> 1x/week but not nightly	Often 7x/week
<b>Impairment</b>	Short-acting beta <sub>2</sub> -agonist use for symptom control (not prevention of EIB)	≤ 2 days/week	> 2 days/week but not > 1x/day	Daily	Several times per day
	Interference with normal activity	None	Minor limitation	Some limitation	Extreme limitation
	Lung function	FEV <sub>1</sub> > 80% predicted	FEV <sub>1</sub> > 80% predicted	FEV <sub>1</sub> > 60% but < 80% predicted	FEV <sub>1</sub> < 60% predicted
	Exacerbations requiring oral systemic corticosteroids	0-1/year (see note)	FEV <sub>1</sub> /FVC normal	FEV <sub>1</sub> /FVC reduced 5% ≥ 2/year (see note)	FEV <sub>1</sub> /FVC reduced > 5%
<b>Risk</b>		Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time for patients in any severity category. Relative annual risk of exacerbations may be related to FEV <sub>1</sub>			
	Recommended Step for initiating Treatment	Step 1	Step 2	Step 3 and consider short course of oral systemic corticosteroids	Step 4

In 2 to 6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.

Wright, 2022

94

# Asthma Findings


- Typically, reversibility of 12% or greater after administration of a bronchodilator aerosol is consistent with asthma.

Conboy-Ellis, Kathleen. Asthma: Pathogenesis and Management. *The Nurse Practitioner*: November 2006; Vol.31, No. 11. 24 – 39.

Wright, 2022

95

95



Wright, 2022

96

96



## Less Common Causes

- Tuberculosis
  - Sputum culture, Mantoux, PCR testing, Chest X-ray
- Bronchogenic carcinoma
  - Chest X-ray, CT scan
- CHF
  - S3, edema, crackles, JVD, weight gain
- Interstitial lung disease
  - Pulmonary fibrosis, amyloidosis
- Psychogenic cough
  - Consider gabapentin

Wright, 2022

97

97

## Refractory Cough

- No benefit to bronchoscopy in most individuals
- Gabapentin and speech therapy may offer benefit
- Pulmonology vs. otolaryngology referral
- Awaiting new medication:
  - Gefapixant: P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough
  - P2X3 receptors are found on sensory nerve fibers in the airway lining

Wright, 2022

98

98

Thank You For Your Time and  
Attention!!!

WendyARNP@aol.com

Wright, 2022

99

99